


PRODUCT: BDA366

ALTERNATE NAME: 1-[[3-(Diethylamino)-2(S)-hydroxypropyl]amino]-4-[(2(S)-oxiranymethyl)amino]-9,10-anthracenedione

CATALOG NUMBER: B1827-5,25

AMOUNT: 5 mg, 25 mg

STRUCTURE:

MOLECULAR FORMULA: C₂₄H₂₉N₃O₄

MOLECULAR WEIGHT: 423.5

CAS NUMBER: 1909226-00-1

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO (>40 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C. Protect from air and light

DESCRIPTION: BDA-366 is a small-molecule Bcl2-BH4 domain antagonist, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer.

REFERENCES: Deng, J., *et al.* (2016). *Oncotarget* 7, 27753-27763.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

A-1210477 (**B1826**)

ABT-737 (**2463**)

AT-101 (**2380**)

Bcl-2 Inhibitor GX15-070 (**2040**)

Gambogic acid (**2785**)

Mcl-1 Antibody (**3035**)

Pyridoclast (**B1817**)

TW-37 (**2789**)

ABT-263 (**Cat. No. 2467-5, 25**)

Bcl2 Inhibitor GX15-070 (**Cat. No. 2040-5**)

Bcl2 Inhibitor ABT-199 (**Cat. No. 2253-1, 5**)

BH3I-1 (**Cat. No. B1277-5,25**)

USAGE:

FOR RESEARCH USE ONLY! Not to be used in humans